Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
Diana N J
DN
Lockwood
Maria Da Graca
Mda G
Cunha
D002991:Clofazimine / Q000008:administration & dosage / Q000009:adverse effects*; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000639:trends; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage*; D007918:Leprosy / Q000188:drug therapy*; D008911:Minocycline / Q000008:administration & dosage*; D009166:Mycobacterium leprae / Q000187:drug effects*; D015242:Ofloxacin / Q000008:administration & dosage*; D010349:Patient Compliance; D012293:Rifampin / Q000008:administration & dosage*; D014944:World Health Organization
D007917:Leprostatic Agents; D003622:Dapsone; D015242:Ofloxacin; D002991:Clofazimine; D008911:Minocycline; D012293:Rifampin